RARA and hepatocellular carcinoma: Mechanistically, we demonstrated that sulfarotene upregulated RARα in HCC TRCs, which downregulated SOS2, an important mediator of oncogenic RAS activation that is critical for multiple upstream as well as downstream signaling pathways.